CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • AVTX Dashboard
  • Financials
  • Filings
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

Avalo Therapeutics (AVTX)

Company Profile
Avalo is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.
Avalo Therapeutics logo

Company profile

Ticker
AVTX
Exchange
NASDAQ
Website
www.avalotx.com
CEO
Michael F. Cola
Employees
Incorporated
Delaware
Location
Maryland
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...
Former names
Cerecor Inc.
SEC CIK
0001534120
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
Medgenics Medical (Israel) Ltd. • Aevi Genomic Medicine Europe ...

AVTX stock data

Latest filings (excl ownership)
View all
8-K
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
17 Jan 23
8-K
Completion of Acquisition or Disposition of Assets
14 Nov 22
S-8
Registration of securities for employees
7 Nov 22
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
7 Nov 22
8-K
Other Events
16 Aug 22
8-K
Avalo Therapeutics Announces Board Changes
11 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
4 Aug 22
8-K
Entry into a Material Definitive Agreement
1 Aug 22
Latest ownership filings
View all
4
Magnus Persson
3 Jan 23
4
June Sherie Almenoff
3 Jan 23
4
GARRY ARTHUR NEIL
12 Dec 22
4
GARRY ARTHUR NEIL
7 Oct 22
4
Christopher Ryan Sullivan
7 Oct 22
4
June Sherie Almenoff
3 Oct 22
4
GILLA KAPLAN
3 Oct 22
4
Magnus Persson
3 Oct 22
SC 13D/A
ARMISTICE CAPITAL, LLC
11 Aug 22
SC 13G/A
Caissa Capital Management ltd.
8 Aug 22

Financial summary

Financial statements Chart AVTX financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 17.18 mm 17.18 mm 17.18 mm 17.18 mm 17.18 mm 17.18 mm
Cash burn (monthly) (no burn) 4.56 mm (no burn) 4.07 mm (no burn) 3.33 mm
Cash used (since last report) n/a 17.79 mm n/a 15.89 mm n/a 12.97 mm
Cash remaining n/a -609.10 k n/a 1.29 mm n/a 4.20 mm
Runway (months of cash) n/a -0.1 n/a 0.3 n/a 1.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

AVTX institutional ownership history Ownership history
67.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 26 55 -52.7%
Opened positions 2 11 -81.8%
Closed positions 31 26 +19.2%
Increased positions 0 7 EXIT
Reduced positions 24 23 +4.3%
13F shares Current Prev Q Change
Total value 21.79 mm 36.31 mm -40.0%
Total shares 6.32 mm 73.50 mm -91.4%
Total puts 0.00 0.00
Total calls 0.00 0.00
Total put/call ratio – – –
Largest owners Shares Value Change
Armistice Capital 3.96 mm $13.16 mm -91.7%
Caissa Capital Management 798.26 k $3.46 mm -80.5%
Nantahala Capital Management 547.81 k $1.82 mm -91.8%
Point72 Asset Management 500.74 k $1.66 mm -91.7%
Vanguard 221.98 k $736.00 k -92.8%
BLK Blackrock 103.41 k $343.00 k -91.7%
Geode Capital Management 51.42 k $170.00 k -93.9%
Millennium Management 51.01 k $169.00 k -95.0%
GS Goldman Sachs 35.64 k $118.00 k -94.5%
Assenagon Asset Management 15.65 k $52.00 k NEW
Largest transactions Shares Bought/sold Change
Armistice Capital 3.96 mm -43.61 mm -91.7%
Nantahala Capital Management 547.81 k -6.16 mm -91.8%
Point72 Asset Management 500.74 k -5.51 mm -91.7%
Caissa Capital Management 798.26 k -3.30 mm -80.5%
Vanguard 221.98 k -2.85 mm -92.8%
BLK Blackrock 103.41 k -1.14 mm -91.7%
Millennium Management 51.01 k -960.07 k -95.0%
Geode Capital Management 51.42 k -794.97 k -93.9%
GS Goldman Sachs 35.64 k -614.01 k -94.5%
Opaleye Management 0.00 -450.00 k EXIT
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

AVTX insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Dec 22 June Sherie Almenoff Stock Option Common Stock Grant Acquire A No No 5.0401 410 2.07 k 410
30 Dec 22 Persson Magnus Stock Option Common Stock Grant Acquire A No No 5.0401 2,536 12.78 k 2,536
9 Dec 22 Neil Garry Arthur Common Stock Buy Acquire P No No 4.42 2,083 9.21 k 9,220
5 Oct 22 Christopher Ryan Sullivan Stock Option Common Stock Grant Acquire A No No 3.97 25,000 99.25 k 25,000
5 Oct 22 Neil Garry Arthur Stock Option Common Stock Grant Acquire A No No 3.97 75,000 297.75 k 75,000
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
23 Jan 23
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its biosensor platform development.
12 Health Care Stocks Moving In Monday's Intraday Session
23 Jan 23
Avalo Announces It Has Completed Targeted Enrollment Of 80 Patients In Phase 2 PEAK Trial Of AVTX-002 In Non-Eosinophilic Asthma
17 Jan 23
Avalo Therapeutics, Inc. (NASDAQ:AVTX), today announced that it completed enrollment of the 80 patients targeted for the Phase 2 PEAK Trial evaluating AVTX-002 (anti-LIGHT mAb) in patients with Non-Eosinophilic Asthma
Looking Into Avalo Therapeutics's Return On Capital Employed
30 Nov 22
Recap: Avalo Therapeutics Q3 Earnings
7 Nov 22

Press releases

From Benzinga Pro
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
7 Nov 22
Topline data expected in the first half of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA)Entered into agreement to sell future economic rights to previously out-licensed assets in
Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million
7 Nov 22
WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), today announced it entered into a purchase agreement to sell its economic rights to future payments for
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn